Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies

Pambis A., Li T., Li Y., Li B., Kim C.

Clinical Trial on Osteoarthritis, Chronic Inflammation, Immune Modulation, published in Stem Cells Int (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cells Int (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42257013
PMCID
PMC13238247
DOI
10.1155/sci/6699734

Abstract (original English)

Osteoarthritis (OA) is the most prevalent degenerative joint disease and a leading cause of pain and disability, yet current treatments remain largely palliative and fail to alter disease progression. Stem cell-based therapies offer a promising alternative, with mesenchymal stromal/stem cells (MSCs) representing the most clinically advanced approach. Preclinical and clinical studies demonstrate that MSCs exert anti-inflammatory, immunomodulatory, chondroprotective, and analgesic effects primarily through paracrine signaling rather than durable engraftment. Clinical trials consistently confirm intra-articular (IA) MSC safety and symptomatic benefit, though structural outcomes remain variable owing to heterogeneity in cell source, dose, and trial design. This recognition has fueled interest in cell-free derivatives, particularly extracellular vesicles (EVs), which recapitulate MSC paracrine functions while offering improved safety, scalability, and regulatory compatibility. In parallel, bioengineering innovations, including hydrogels, scaffolds, 3D bioprinting, nanotechnology, and genetic enhancement, are being leveraged to prolong persistence, optimize delivery, and enable adaptive, multimodal repair. Emerging sources such as induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), and joint-resident progenitors further expand the regenerative toolkit. These developm

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research